Gastric cancer molecular classification based on immunohistochemistry and in-situ hybridisation and mortality

dc.contributor.authorEskuri Maarit
dc.contributor.authorBirkman Eva-Maria
dc.contributor.authorKauppila Joonas H
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code2607100
dc.converis.publication-id393521355
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/393521355
dc.date.accessioned2025-08-28T01:06:20Z
dc.date.available2025-08-28T01:06:20Z
dc.description.abstract<p><strong>Background and aims: </strong>Gastric cancers (GC) are divided into subtypes based on molecular profile: Epstein-Barr virus (EBV)-positive, microsatellite instability (MSI), chromosomal instability (CIN) and genomically stable (GS) tumours. The prognostic impact of this classification is unclear. The aim was to evaluate whether the molecular subtypes determined using in-situ hybridisation (ISH) and immunohistochemistry (IHC) are associated with clinicopathological parameters and prognosis.</p><p><strong>Methods and results: </strong>The study included 503 GC patients. Based on ISH (EBV) and IHC (MSI and TP53), tumours were divided into EBV-positive, MSI, CIN (EBVneg/MSS/TP53aberrant) and GS (EBVneg/MSS/TP53wild-type) subgroups. Survival analyses with intestinal- and diffuse-type tumours were examined separately. EBV-positive tumours associated with male sex. Both EBV-positive and MSI tumours associated with intestinal type. CIN tumours associated with intestinal-type and positive lymph node status. GS tumours associated with diffuse-type and negative lymph node status. In the total cohort, no significant differences in the 5-year survival were observed. In intestinal tumours, the 5-year survival was better in EBV-positive tumours compared with GS tumours [hazard ratio (HR) = 0.57, 95% confidence interval (CI) = 0.33-0.99]. In diffuse tumours, the 5-year survival was worse in CIN tumours compared with GS tumours (HR = 1.57, 95% CI = 1.14-2.18). In radically resected diffuse tumours, the 5-year survival was worse in MSI tumours compared with GS tumours (HR = 3.26, 95% CI = 1.20-8.82).</p><p><strong>Conclusions: </strong>The molecular classification is associated with histological type but not prognosis in GC. As the prognostic effects of molecular subtypes in intestinal- and diffuse-type cancers may differ, combining histological and molecular information is recommended for future studies.</p>
dc.format.pagerange327
dc.format.pagerange337
dc.identifier.eissn1365-2559
dc.identifier.jour-issn0309-0167
dc.identifier.olddbid207026
dc.identifier.oldhandle10024/190053
dc.identifier.urihttps://www.utupub.fi/handle/11111/49907
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/his.15207
dc.identifier.urnURN:NBN:fi-fe2025082787537
dc.language.isoen
dc.okm.affiliatedauthorBirkman, Eva-Maria
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWiley-Blackwell
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1111/his.15207
dc.relation.ispartofjournalHistopathology
dc.relation.issue2
dc.relation.volume85
dc.source.identifierhttps://www.utupub.fi/handle/10024/190053
dc.titleGastric cancer molecular classification based on immunohistochemistry and in-situ hybridisation and mortality
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Histopathology - 2024 - Eskuri - Gastric cancer molecular classification based on.pdf
Size:
1.63 MB
Format:
Adobe Portable Document Format